Swiss National Bank Grows Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Swiss National Bank grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 12.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 149,600 shares of the company's stock after buying an additional 16,500 shares during the quarter. Swiss National Bank owned approximately 0.17% of IDEAYA Biosciences worth $3,845,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of IDYA. Rhumbline Advisers raised its stake in IDEAYA Biosciences by 0.5% in the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock worth $2,919,000 after buying an additional 585 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after purchasing an additional 853 shares during the period. Assetmark Inc. boosted its position in shares of IDEAYA Biosciences by 2.5% during the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company's stock valued at $1,163,000 after purchasing an additional 1,084 shares in the last quarter. R Squared Ltd purchased a new stake in IDEAYA Biosciences in the fourth quarter worth $35,000. Finally, Bellevue Group AG raised its holdings in IDEAYA Biosciences by 26.3% in the third quarter. Bellevue Group AG now owns 7,200 shares of the company's stock worth $228,000 after purchasing an additional 1,500 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on IDYA. Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Stephens reiterated an "overweight" rating and set a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Wedbush reissued an "outperform" rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $53.58.

Remove Ads

IDEAYA Biosciences Trading Down 2.2 %

NASDAQ:IDYA traded down $0.38 during mid-day trading on Friday, reaching $17.05. The company's stock had a trading volume of 554,142 shares, compared to its average volume of 859,048. The stock has a market cap of $1.49 billion, a P/E ratio of -5.17 and a beta of 0.76. The firm's fifty day moving average price is $20.80 and its two-hundred day moving average price is $25.84. IDEAYA Biosciences, Inc. has a 12-month low of $16.88 and a 12-month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to analysts' expectations of $7.00 million. Analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.